<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37481656</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Neuroimmune characterization of optineurin insufficiency mouse model during ageing.</ArticleTitle><Pagination><StartPage>11840</StartPage><MedlinePgn>11840</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11840</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-38875-3</ELocationID><Abstract><AbstractText>Optineurin is a multifunctional polyubiquitin-binding protein implicated in inflammatory signalling. Optineurin mutations are associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), neurodegenerative diseases characterised by neuronal loss, neuroinflammation, and peripheral immune disbalance. However, the pathogenic role of optineurin mutations is unclear. We previously observed no phenotype in the unmanipulated young optineurin insufficiency mice (Optn<sup>470T</sup>), designed to mimic ALS/FTD-linked truncations deficient in polyubiquitin binding. The purpose of this study was to investigate whether ageing would trigger neurodegeneration. We performed a neurological, neuropathological, and immunological characterization of ageing wild-type (WT) and Optn<sup>470T</sup> mice. No motor or cognitive differences were detected between the genotypes. Neuropathological analyses demonstrated signs of ageing including lipofuscin accumulation and microglial activation in WT mice. However, this was not worsened in Optn<sup>470T</sup> mice, and they did not exhibit TAR DNA-binding protein 43 (TDP-43) aggregation or neuronal loss. Spleen immunophenotyping uncovered T cell immunosenescence at two years but without notable differences between the WT and Optn<sup>470T</sup> mice. Conventional dendritic cells (cDC) and macrophages exhibited increased expression of activation markers in two-year-old Optn<sup>470T</sup> males but not females, although the numbers of innate immune cells were similar between genotypes. Altogether, a combination of optineurin insufficiency and ageing did not induce ALS/FTD-like immune imbalance and neuropathology in mice.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mohovic</LastName><ForeName>Nikolina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Immunology, Department of Biotechnology, University of Rijeka, Radmile Matejcic 2, 51000, Rijeka, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Peradinovic</LastName><ForeName>Josip</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Immunology, Department of Biotechnology, University of Rijeka, Radmile Matejcic 2, 51000, Rijeka, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markovinovic</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Immunology, Department of Biotechnology, University of Rijeka, Radmile Matejcic 2, 51000, Rijeka, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, 5 Cutcombe Road, London, SE5 9RX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cimbro</LastName><ForeName>Raffaello</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Immunology, Department of Biotechnology, University of Rijeka, Radmile Matejcic 2, 51000, Rijeka, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minic</LastName><ForeName>Zeljka</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, University of Rijeka, Radmile Matejcic 2, 51000, Rijeka, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dominovic</LastName><ForeName>Marin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, University of Rijeka, Radmile Matejcic 2, 51000, Rijeka, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakovac</LastName><ForeName>Hrvoje</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology and Immunology, Medical Faculty, University of Rijeka, Brace Branchetta 20, 51000, Rijeka, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nimac</LastName><ForeName>Jerneja</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Jozef Stefan Institute, 1000, Ljubljana, Slovenia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Biomedicine, Faculty of Medicine, University of Ljubljana, 1000, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogelj</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Jozef Stefan Institute, 1000, Ljubljana, Slovenia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Chemistry and Chemical Technology, University of Ljubljana, 1000, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munitic</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Immunology, Department of Biotechnology, University of Rijeka, Radmile Matejcic 2, 51000, Rijeka, Croatia. ivana.munitic@biotech.uniri.hr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>120904-94-1</RegistryNumber><NameOfSubstance UI="D025821">Polyubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025821" MajorTopicYN="N">Polyubiquitin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>23</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>22</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37481656</ArticleId><ArticleId IdType="pmc">PMC10363168</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-38875-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-38875-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;land L-C, et al. Immunity in amyotrophic lateral sclerosis: Blurred lines between excessive inflammation and inefficient immune responses. Brain Commun. 2020;2:fcaa124. doi: 10.1093/braincomms/fcaa124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa124</ArticleId><ArticleId IdType="pmc">PMC7585698</ArticleId><ArticleId IdType="pubmed">33134918</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchi F, et al. Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neurosci. Biobehav. Rev. 2021;127:958&#x2013;978. doi: 10.1016/j.neubiorev.2021.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2021.06.027</ArticleId><ArticleId IdType="pmc">PMC8428677</ArticleId><ArticleId IdType="pubmed">34153344</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P, Beckers J, Gossye H, Van Damme P. The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD. Mol. Neurodegener. 2022;17:22. doi: 10.1186/s13024-022-00525-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00525-z</ArticleId><ArticleId IdType="pmc">PMC8932121</ArticleId><ArticleId IdType="pubmed">35303907</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. (Berl.) 2019;137:715&#x2013;730. doi: 10.1007/s00401-018-1933-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1933-9</ArticleId><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;226. doi: 10.1038/nature08971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol. (Berl.) 2012;123:395&#x2013;407. doi: 10.1007/s00401-011-0932-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0932-x</ArticleId><ArticleId IdType="pmc">PMC3595560</ArticleId><ArticleId IdType="pubmed">22210083</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18:631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson-Stone C, et al. CYLD is a causative gene for frontotemporal dementia&#x2014;Amyotrophic lateral sclerosis. Brain. 2020;143:783&#x2013;799. doi: 10.1093/brain/awaa039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa039</ArticleId><ArticleId IdType="pmc">PMC7089666</ArticleId><ArticleId IdType="pubmed">32185393</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, et al. Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: A case report. Amyotroph. Lateral Scler. Front. Degener. 2018;19:469&#x2013;471. doi: 10.1080/21678421.2018.1452947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1452947</ArticleId><ArticleId IdType="pmc">PMC6116528</ArticleId><ArticleId IdType="pubmed">29558868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353:603&#x2013;608. doi: 10.1126/science.aaf6803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6803</ArticleId><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu G, Wu C-J, Zhao Y, Ashwell JD. Optineurin negatively regulates TNF&#x3b1;- induced NF-&#x3ba;B activation by competing with NEMO for ubiquitinated RIP. Curr. Biol. 2007;17:1438&#x2013;1443. doi: 10.1016/j.cub.2007.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2007.07.041</ArticleId><ArticleId IdType="pubmed">17702576</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleason CE, Ordureau A, Gourlay R, Arthur JSC, Cohen P. Polyubiquitin binding to optineurin is required for optimal activation of TANK-binding kinase 1 and production of interferon &#x3b2;. J. Biol. Chem. 2011;286:35663&#x2013;35674. doi: 10.1074/jbc.M111.267567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.267567</ArticleId><ArticleId IdType="pmc">PMC3195586</ArticleId><ArticleId IdType="pubmed">21862579</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, et al. ALS-associated E478G mutation in human OPTN (optineurin) promotes inflammation and induces neuronal cell death. Front. Immunol. 2018;9:2647. doi: 10.3389/fimmu.2018.02647.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02647</ArticleId><ArticleId IdType="pmc">PMC6251386</ArticleId><ArticleId IdType="pubmed">30519240</ArticleId></ArticleIdList></Reference><Reference><Citation>Prtenjaca N. Optineurin dysfunction in amyotrophic lateral sclerosis: Why so puzzling? Period. Biol. 2020;121&#x2013;122:23&#x2013;34. doi: 10.18054/pb.v121-122i1-2.10627.</Citation><ArticleIdList><ArticleId IdType="doi">10.18054/pb.v121-122i1-2.10627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurashige T, et al. Optineurin defects cause TDP43-pathology with autophagic vacuolar formation. Neurobiol. Dis. 2021;148:105215. doi: 10.1016/j.nbd.2020.105215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105215</ArticleId><ArticleId IdType="pubmed">33296728</ArticleId></ArticleIdList></Reference><Reference><Citation>Moharir SC, Swarup G. Optineurin deficiency induces patchy hair loss but it is not sufficient to cause amyotrophic lateral sclerosis in mice. Biochim. Biophys. Acta BBA Mol. Basis Dis. 2022;1868:166470. doi: 10.1016/j.bbadis.2022.166470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2022.166470</ArticleId><ArticleId IdType="pubmed">35750266</ArticleId></ArticleIdList></Reference><Reference><Citation>Slowicka K, et al. Optineurin deficiency in mice is associated with increased sensitivity to Salmonella but does not affect proinflammatory NF-&#x3ba;B signaling. Eur. J. Immunol. 2016;46:971&#x2013;980. doi: 10.1002/eji.201545863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201545863</ArticleId><ArticleId IdType="pubmed">26677802</ArticleId></ArticleIdList></Reference><Reference><Citation>Markovinovic A, Ljutic T, B&#xe9;land L-C, Munitic I. Optineurin insufficiency disbalances proinflammatory and anti-inflammatory factors by reducing microglial IFN-&#x3b2; responses. Neuroscience. 2018;388:139&#x2013;151. doi: 10.1016/j.neuroscience.2018.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2018.07.007</ArticleId><ArticleId IdType="pubmed">30017954</ArticleId></ArticleIdList></Reference><Reference><Citation>Peradinovic J, et al. Ageing-induced decline in primary myeloid cell phagocytosis is unaffected by optineurin insufficiency. Biology. 2023;12:240. doi: 10.3390/biology12020240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology12020240</ArticleId><ArticleId IdType="pmc">PMC9953198</ArticleId><ArticleId IdType="pubmed">36829517</ArticleId></ArticleIdList></Reference><Reference><Citation>Prtenjaca N, et al. Optineurin deficiency and insufficiency lead to higher microglial TDP-43 protein levels. Int. J. Mol. Sci. 2022;23:6829. doi: 10.3390/ijms23126829.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23126829</ArticleId><ArticleId IdType="pmc">PMC9224222</ArticleId><ArticleId IdType="pubmed">35743272</ArticleId></ArticleIdList></Reference><Reference><Citation>Markovinovic A, et al. Optineurin in amyotrophic lateral sclerosis: Multifunctional adaptor protein at the crossroads of different neuroprotective mechanisms. Prog. Neurobiol. 2017;154:1&#x2013;20. doi: 10.1016/j.pneurobio.2017.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2017.04.005</ArticleId><ArticleId IdType="pubmed">28456633</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Arumugam TV. Hallmarks of brain aging: Adaptive and pathological modification by metabolic states. Cell Metab. 2018;27:1176&#x2013;1199. doi: 10.1016/j.cmet.2018.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2018.05.011</ArticleId><ArticleId IdType="pmc">PMC6039826</ArticleId><ArticleId IdType="pubmed">29874566</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschi C, et al. Inflamm-aging: An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 2000;908:244&#x2013;254. doi: 10.1111/j.1749-6632.2000.tb06651.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2000.tb06651.x</ArticleId><ArticleId IdType="pubmed">10911963</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogilenko DA, Shchukina I, Artyomov MN. Immune ageing at single-cell resolution. Nat. Rev. Immunol. 2022;22:484&#x2013;498. doi: 10.1038/s41577-021-00646-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00646-4</ArticleId><ArticleId IdType="pmc">PMC8609266</ArticleId><ArticleId IdType="pubmed">34815556</ArticleId></ArticleIdList></Reference><Reference><Citation>Norden DM, Godbout JP. Review: Microglia of the aged brain: Primed to be activated and resistant to regulation. Neuropathol. Appl. Neurobiol. 2013;39:19&#x2013;34. doi: 10.1111/j.1365-2990.2012.01306.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2012.01306.x</ArticleId><ArticleId IdType="pmc">PMC3553257</ArticleId><ArticleId IdType="pubmed">23039106</ArticleId></ArticleIdList></Reference><Reference><Citation>Munitic I, et al. Optineurin insufficiency impairs IRF3 but Not NF-&#x3ba;B activation in immune cells. J. Immunol. 2013;191:6231&#x2013;6240. doi: 10.4049/jimmunol.1301696.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1301696</ArticleId><ArticleId IdType="pmc">PMC3886234</ArticleId><ArticleId IdType="pubmed">24244017</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:1324&#x2013;1329. doi: 10.1126/science.aaf1064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1064</ArticleId><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436&#x2013;1441. doi: 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchi F, et al. Emerging trends in the field of inflammation and proteinopathy in ALS/FTD spectrum disorder. Biomedicines. 2023;11:1599. doi: 10.3390/biomedicines11061599.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11061599</ArticleId><ArticleId IdType="pmc">PMC10295684</ArticleId><ArticleId IdType="pubmed">37371694</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S, et al. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J. Neuroimmunol. 2009;210:73&#x2013;79. doi: 10.1016/j.jneuroim.2009.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2009.02.012</ArticleId><ArticleId IdType="pubmed">19307024</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2013;5:64&#x2013;79. doi: 10.1002/emmm.201201544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, et al. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. 2017;74:1446&#x2013;1454. doi: 10.1001/jamaneurol.2017.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusconi M, et al. Inflammatory role of dendritic cells in Amyotrophic Lateral Sclerosis revealed by an analysis of patients&#x2019; peripheral blood. Sci. Rep. 2017;7:7853. doi: 10.1038/s41598-017-08233-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-08233-1</ArticleId><ArticleId IdType="pmc">PMC5552769</ArticleId><ArticleId IdType="pubmed">28798369</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi H, Wu Z. Microglia-aging: roles of microglial lysosome- and mitochondria-derived reactive oxygen species in brain aging. Behav. Brain Res. 2009;201:1&#x2013;7. doi: 10.1016/j.bbr.2009.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2009.02.001</ArticleId><ArticleId IdType="pubmed">19428609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishioka T, Shimizu J, Iida R, Yamazaki S, Sakaguchi S. CD4+CD25+Foxp3+ T cells and CD4+CD25&#x2212;Foxp3+ T cells in aged mice. J. Immunol. 2006;176:6586&#x2013;6593. doi: 10.4049/jimmunol.176.11.6586.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.11.6586</ArticleId><ArticleId IdType="pubmed">16709816</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada M, et al. Clinicopathologic features of autosomal recessive amyotrophic lateral sclerosis associated with optineurin mutation: Autosomal recessive OPTN-ALS. Neuropathology. 2014;34:64&#x2013;70. doi: 10.1111/neup.12051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12051</ArticleId><ArticleId IdType="pubmed">23889540</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermentzaki G, et al. Deletion of Ripk3 prevents motor neuron death in vitro but not in vivo. eNeuro. 2019 doi: 10.1523/ENEURO.0308-18.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0308-18.2018</ArticleId><ArticleId IdType="pmc">PMC6391588</ArticleId><ArticleId IdType="pubmed">30815534</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanagi T, et al. Appearance of phagocytic microglia adjacent to motoneurons in spinal cord tissue from a presymptomatic transgenic rat model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2010 doi: 10.1002/jnr.22424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22424</ArticleId><ArticleId IdType="pubmed">20648658</ArticleId></ArticleIdList></Reference><Reference><Citation>Escartin C, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci. 2021;24:312&#x2013;325. doi: 10.1038/s41593-020-00783-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00783-4</ArticleId><ArticleId IdType="pmc">PMC8007081</ArticleId><ArticleId IdType="pubmed">33589835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, et al. Clinicopathologic study on an ALS family with a heterozygous E478G optineurin mutation. Acta Neuropathol. (Berl.) 2011;122:223&#x2013;229. doi: 10.1007/s00401-011-0842-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0842-y</ArticleId><ArticleId IdType="pubmed">21644038</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdewyn S, et al. Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T)mice. Mol. Neurodegener. 2014;9:24. doi: 10.1186/1750-1326-9-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-24</ArticleId><ArticleId IdType="pmc">PMC4088917</ArticleId><ArticleId IdType="pubmed">24938805</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourcelot M, et al. The Golgi apparatus acts as a platform for TBK1 activation after viral RNA sensing. BMC Biol. 2016;14:69. doi: 10.1186/s12915-016-0292-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12915-016-0292-z</ArticleId><ArticleId IdType="pmc">PMC4991008</ArticleId><ArticleId IdType="pubmed">27538435</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, et al. Optineurin modulates the maturation of dendritic cells to regulate autoimmunity through JAK2-STAT3 signaling. Nat. Commun. 2021;12:6198. doi: 10.1038/s41467-021-26477-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26477-4</ArticleId><ArticleId IdType="pmc">PMC8551263</ArticleId><ArticleId IdType="pubmed">34707127</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020;585:96&#x2013;101. doi: 10.1038/s41586-020-2625-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2625-x</ArticleId><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruno C, et al. Haploinsufficiency of TANK-binding kinase 1 prepones age-associated neuroinflammatory changes without causing motor neuron degeneration in aged mice. Brain Commun. 2020;2:fcaa133. doi: 10.1093/braincomms/fcaa133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa133</ArticleId><ArticleId IdType="pmc">PMC7519725</ArticleId><ArticleId IdType="pubmed">33005894</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerbino V, et al. The loss of TBK1 kinase activity in motor neurons or in all cell types differentially impacts ALS disease progression in SOD1 mice. Neuron. 2020;106:789&#x2013;805.e5. doi: 10.1016/j.neuron.2020.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.03.005</ArticleId><ArticleId IdType="pubmed">32220666</ArticleId></ArticleIdList></Reference><Reference><Citation>Toth RP, Atkin JD. Dysfunction of optineurin in amyotrophic lateral sclerosis and glaucoma. Front. Immunol. 2018;9:1017. doi: 10.3389/fimmu.2018.01017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01017</ArticleId><ArticleId IdType="pmc">PMC5974248</ArticleId><ArticleId IdType="pubmed">29875767</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, et al. Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. J. Exp. Med. 2019;216:267&#x2013;278. doi: 10.1084/jem.20180729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180729</ArticleId><ArticleId IdType="pmc">PMC6363427</ArticleId><ArticleId IdType="pubmed">30635357</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V, Valdmanis PN, Gould PV, Julien J-P, Dupr&#xe9; N. From animal models to human disease: A genetic approach for personalized medicine in ALS. Acta Neuropathol. Commun. 2016;4:70. doi: 10.1186/s40478-016-0340-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0340-5</ArticleId><ArticleId IdType="pmc">PMC4940869</ArticleId><ArticleId IdType="pubmed">27400686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino T, et al. Nearly 30 years of animal models to study amyotrophic lateral sclerosis: A historical overview and future perspectives. Int. J. Mol. Sci. 2021;22:12236. doi: 10.3390/ijms222212236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222212236</ArticleId><ArticleId IdType="pmc">PMC8619465</ArticleId><ArticleId IdType="pubmed">34830115</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, et al. The multistep hypothesis of ALS revisited: The role of genetic mutations. Neurology. 2018;91:e635&#x2013;e642. doi: 10.1212/WNL.0000000000005996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005996</ArticleId><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: A population-based modelling study. Lancet Neurol. 2014;13:1108&#x2013;1113. doi: 10.1016/S1474-4422(14)70219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Leger M, et al. Object recognition test in mice. Nat. Protoc. 2013;8:2531&#x2013;2537. doi: 10.1038/nprot.2013.155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.155</ArticleId><ArticleId IdType="pubmed">24263092</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampathu DM, et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am. J. Pathol. 2006;169:1343&#x2013;1352. doi: 10.2353/ajpath.2006.060438.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.060438</ArticleId><ArticleId IdType="pmc">PMC1780184</ArticleId><ArticleId IdType="pubmed">17003490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-K, Tansey MG. Microglia isolation from adult mouse brain. Methods Mol. Biol. Clifton NJ. 2013;1041:17&#x2013;23. doi: 10.1007/978-1-62703-520-0_3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-520-0_3</ArticleId><ArticleId IdType="pmc">PMC4145600</ArticleId><ArticleId IdType="pubmed">23813365</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>